Back to search
High-Risk Non-Muscle-Invasive Bladder Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which High-Risk Non-Muscle-Invasive Bladder Cancer trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which High-Risk Non-Muscle-Invasive Bladder Cancer trials you may qualify forNon-muscle-invasive bladder cancer (NMIBC) is usually treated with surgery to remove the tumor (transurethral resection of bladder tumor, or TURBT), often follo…
The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T…
The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or…
This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radia…
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC.…
Researchers are looking for new ways to treat high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of th…
The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1),…
The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder canc…